Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › pemetrexed

pemetrexed

10 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of pemetrexed

165 trials tracked of pemetrexed: 52 in phase 3 or 4 and 31 with published results. The most-cited published study has 3385 citations.

165Trials tracked
52Phase 3 & 4
0Recruiting
31With published results
Phase distribution
Phase 4 2 Phase 3 50 Phase 2 90 Phase 1 19 Other / NA 4
  1. Phase 3 Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) Completed · 3,385 cited
  2. Phase 3 An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) Completed · 2,894 cited
  3. Phase 3 An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Completed · 2,588 cited
  4. Phase 3 A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110] Completed · 1,726 cited
  5. Phase 3 A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Completed · 1,705 cited
  6. Phase 3 A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC Completed · 1,391 cited
Show 44 more trials
  1. Phase 3 Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients Completed · 1,222 cited
  2. Phase 3 Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) Completed · 1,169 cited
  3. Phase 3 LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer Completed · 1,163 cited
  4. Phase 3 Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189) Completed · 701 cited
  5. Phase 3 LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Completed · 583 cited
  6. Phase 3 Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC Completed · 403 cited
  7. Phase 3 Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib Completed · 348 cited
  8. Phase 3 A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer Completed · 289 cited
  9. Phase 3 A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) Completed · 219 cited
  10. Phase 3 A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132) Completed · 188 cited
  11. Phase 3 Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer Completed · 183 cited
  12. Phase 3 A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy Completed · 161 cited
  13. Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789) Completed · 157 cited
  14. Phase 3 First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin Completed · 132 cited
  15. Phase 3 Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma Completed · 104 cited
  16. Phase 3 Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study Completed · 102 cited
  17. Phase 3 Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study Completed · 58 cited
  18. Phase 3 A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Completed · 46 cited
  19. Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers Completed · 30 cited
  20. Phase 3 Avelumab in First-line NSCLC (JAVELIN Lung 100) Completed · 23 cited
  21. Phase 3 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) Completed · 15 cited
  22. Phase 3 Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006) Completed · 11 cited
  23. Phase 3 Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) Completed · 10 cited
  24. Phase 3 BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma Completed · 5 cited
  25. Phase 3 A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer Completed · 4 cited
  26. Phase 4 Chemotherapy for Patients With Non-Small Cell Lung Cancer Completed
  27. Phase 4 A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients Completed
  28. Phase 3 Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study Completed
  29. Phase 3 A Study for Patients With Head and Neck Cancer Completed
  30. Phase 3 Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC) Completed
  31. Phase 3 A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer Completed
  32. Phase 3 AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer Completed
  33. Phase 3 Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC Completed
  34. Phase 3 BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation Completed
  35. Phase 3 Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC) Completed
  36. Phase 3 A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer Completed
  37. Phase 3 A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer Completed
  38. Phase 3 Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients Completed
  39. Phase 3 Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer Completed
  40. Phase 3 An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene Completed
  41. Phase 3 Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer Completed
  42. Phase 3 A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer Completed
  43. Phase 3 Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer Completed
  44. Phase 3 Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer Completed

Showing the 50 most-cited and recently-updated of 165 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Ivonescimab Combined With Chemotherapy Improves Progression Free Survival in EGFR Mutated NSCLC
Oncology RCT
Ivonescimab Combined With Chemotherapy Improves Progression Free Survival in EGFR Mutated NSCLC Trial shows ivonescimab plus chemotherapy improves lung cancer outcomes
Ivonescimab plus pemetrexed and carboplatin significantly extends progression-free survival for patients with advanced EGFR-mutated NSCLC.
A new treatment combination involving ivonescimab and chemotherapy showed a significant improvement in progression-free survival for certain…
Sep 10, 2026
Osimertinib plus chemotherapy improves progression-free survival by 18.4 months in TP53 and EGFR-mutated NSCLC
Pulmonology & Critical Care RCT
Osimertinib plus chemotherapy improves progression-free survival by 18.4 months in TP53 and EGFR-mutated NSCLC Adding chemotherapy to osimertinib extends survival for specific lung cancer
This Phase 3 randomized clinical trial of 294 treatment-naive, stage IV or recurrent nonsquamous NSCLC patients with concurrent TP53 and EGF…
A new combination of osimertinib and chemotherapy significantly extends the time patients with specific lung cancer mutations live without d…
JAMA Sep 8, 2026
Sunvozertinib improves progression-free survival in patients with advanced NSCLC and EGFR exon 20 mutations
Oncology RCT
Sunvozertinib improves progression-free survival in patients with advanced NSCLC and EGFR exon 20 mutations New drug shows promise for specific type of lung cancer
This trial compared sunvozertinib against carboplatin and pemetrexed in patients with advanced nonsquamous NSCLC featuring EGFR exon 20 inse…
A new drug called sunvozertinib may help patients with a specific lung cancer mutation live longer without their tumors growing.
Aug 21, 2026
Ivonescimab plus chemotherapy improves overall survival in patients with EGFR-variant nonsquamous NSCLC
Oncology RCT
Ivonescimab plus chemotherapy improves overall survival in patients with EGFR-variant nonsquamous NSCLC Trial shows ivonescimab extends life for certain lung cancer patients
Researchers evaluated the addition of ivonescimab to pemetrexed and carboplatin chemotherapy for patients with advanced NSCLC who previously…
A new drug combination showed a significant improvement in survival rates for patients with specific types of advanced lung cancer.
JAMA Jul 31, 2026
Evaluating Bevacizumab Addition to Atezolizumab Carboplatin and Pemetrexed in Nonsquamous NSCLC
Pulmonology & Critical Care RCT
Evaluating Bevacizumab Addition to Atezolizumab Carboplatin and Pemetrexed in Nonsquamous NSCLC Trial shows bevacizumab addition has mixed results for lung cancer
A Phase III trial assessed adding bevacizumab to a standard triplet regimen for advanced nonsquamous NSCLC, showing no significant OS improv…
A Phase 3 trial found that adding bevacizumab to a standard drug combination did not improve overall survival for most patients with advance…
Jul 26, 2026
Aumolertinib Combined with Chemotherapy Improves Progression Free Survival in EGFR Mutated NSCLC
Pulmonology & Critical Care RCT
Aumolertinib Combined with Chemotherapy Improves Progression Free Survival in EGFR Mutated NSCLC Combination therapy extends progression free survival in lung cancer
Phase 3 trial results show aumolertinib plus chemotherapy significantly extends progression-free survival compared to monotherapy for advanc…
A new trial shows that combining a specific drug with chemotherapy helps patients with advanced lung cancer live longer without their diseas…
Jul 4, 2026
Osimertinib treatment for EGFR-mutated NSCLC results in hypertension as the most common CVAE
Pulmonology & Critical Care Meta-analysis
Osimertinib treatment for EGFR-mutated NSCLC results in hypertension as the most common CVAE Osimertinib treatment for lung cancer shows specific heart risks
This meta-analysis of 10,316 patients with EGFR-mutated non-small cell lung cancer evaluated cardiovascular adverse events (CVAEs) associate…
New data identifies hypertension as the most common heart-related side effect for patients taking osimertinib for certain types of lung canc…
Jul 4, 2026
Systematic review of intrathecal therapy for leptomeningeal metastasis in non-small cell lung cancer
Drug Pipeline Meta-analysis
Systematic review of intrathecal therapy for leptomeningeal metastasis in non-small cell lung cancer Intrathecal therapy may help some lung cancer patients with brain lining spread
This systematic review evaluates intrathecal therapy for adult patients with NSCLC-related leptomeningeal metastasis using ten original stud…
A review of ten studies suggests intrathecal therapy can improve symptoms and clear cancer cells from spinal fluid for some lung cancer pati…
Frontiers May 20, 2026
Pembrolizumab improves overall survival versus chemotherapy in Chinese patients with advanced NSCLC and PD-L1 expression
Pulmonology & Critical Care RCT
Pembrolizumab improves overall survival versus chemotherapy in Chinese patients with advanced NSCLC and PD-L1 expression Five-year follow-up shows pembrolizumab extends life for Chinese lung cancer patients with high PD-L1
This Phase 3 trial evaluated pembrolizumab monotherapy against chemotherapy in Chinese patients with previously untreated locally advanced o…
A five-year look at a Chinese lung cancer trial shows pembrolizumab improved survival compared to chemotherapy for patients with high PD-L1 …
May 1, 2026
Pemetrexed use associated with disproportionate reporting of blood, endocrine, and renal disorders in FAERS data
Rheumatology Cohort
Pemetrexed use associated with disproportionate reporting of blood, endocrine, and renal disorders in FAERS data Your Lung Cancer Drug May Have Side Effects Not on the Label
This pharmacovigilance study analyzed 27,098 pemetrexed-associated reports in the US FAERS database from 2004 to 2024.
A safety review of over 27,000 reports found that the lung cancer drug pemetrexed may cause side effects not currently listed on its officia…
Frontiers Apr 16, 2026